Jolana Cermanova

Jolana Cermanova

Auto-generated profile, based on publicly available information

Jolana Cermanova

Department of Pharmacology, Charles University in Prague, Faculty of Medicine in Hradec Kralove, Czech Republic

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
VSVit Sestak
Vit Sestak
JSJan Stariat
Jan Stariat
JCJolana Cermanova
Jolana Cermanova
EPEliska Potuckova
Eliska Potuckova
JCJaroslav Chladek
Jaroslav Chladek
PKPetra Kovarikova
Petra Kovarikova
Novel and potent anti-tumor and anti-metastatic di-2-pyridylketone thiosemicarbazones demonstrate marked differences in pharmacology between the first and second generation lead agents

1 January 2009 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
EBEva Brcakova
Eva Brcakova
LFLeos Fuksa
Leos Fuksa
JCJolana Cermanova
Jolana Cermanova
GKGabriela Kolouchova
Gabriela Kolouchova
MHMilos Hroch
Milos Hroch
SMStanislav Micuda
Stanislav Micuda
Methotrexate (MTX), an important anticancer and immunosuppressive agent, has been suggested for the treatment of primary biliary cirrhosis. However, the drug's pharmacodynamics and toxicity is dependent on its concentrations in plasma which in turn are directly related to MTX's elimination in the liver and kidney. Therefore, the aim of this study was to evaluate changes in MTX biliary and renal excretion during either intrahepatic or obstructive cholestasis in rats. The steady state pharmacokinetic parameters of MTX were evaluated in rats one (BDO1) or seven (BDO7) days after bile duct obstruction (BDO) or 18 h after administration of lipopolysaccharide (LPS). In comparison to the respective control groups, biliary and total clearances of MTX were decreased to 12% and 49% in the BDO1 group, to 5% and 56% in the BDO7 animals, and to 42% and 43% in the LPS group, respectively. Renal clearance of MTX was unchanged in BDO groups, but decreased to 23% of controls in the LPS animals. The serum biochemistry and expression of main hepatic MTX transporters (Mrp2, Mrp3, Mrp4, Bcrp, Oatp1a1, Oatp1a4 and Oatp1b2) confirmed the pathological cholestatic changes in the liver and partly elucidated the cause of changes in MTX pharmacokinetic parameters. In conclusion, this study is the first describing marked alteration of MTX hepatic and renal elimination induced by cholestasis in rats. Moreover, the reported changes in MTX pharmacokinetics and respective transporter expression suggest important mechanistic differences between the two widely used cholestatic models.

1 January 2013 in Toxicology
Verified
Journal Article
Closed access
PHPetra Hirsova
Petra Hirsova
GKGabriela Karlasova
Gabriela Karlasova
EDEva Dolezelova
Eva Dolezelova
JCJolana Cermanova
Jolana Cermanova
MZMarie Zagorova
Marie Zagorova
SMStanislav Micuda
Stanislav Micuda

11 February 2009 in International Orthopaedics
Verified
Journal Article
Closed access
PDF file
EPEgon Prochazka
Egon Prochazka
TSTomáš Soukup
Tomáš Soukup
MHMilos Hroch
Milos Hroch
LFLeos Fuksa
Leos Fuksa
EBEva Brcakova
Eva Brcakova
SMStanislav Micuda
Stanislav Micuda

1 September 2012 in European Journal of Pharmacology
Verified
Journal Article
Closed access
PHPetra Hirsova
Petra Hirsova
GKGabriela Kolouchova
Gabriela Kolouchova
EDEva Dolezelova
Eva Dolezelova
JCJolana Cermanova
Jolana Cermanova
RHRadomir Hyspler
Radomir Hyspler
SMStanislav Micuda
Stanislav Micuda

23 February 2007 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
SMStanislav Micuda
Stanislav Micuda
LFLeos Fuksa
Leos Fuksa
LMLucie Mundlova
Lucie Mundlova
JOJan Osterreicher
Jan Osterreicher
JMJaroslav Mokry
Jaroslav Mokry
JMJirina Martinkova
Jirina Martinkova